BRAF and neoplasm: After administration of a BRAFi in a BRAF-mutant melanoma model, CD40 ligand and interferon-gamma expression was increased on intratumoral CD4+ tumor-infiltrating lymphocytes (TIL), and regulatory T-cells and myeloid cells were decreased (5), suggesting anti-tumor modulation of the TME.